Kura Oncology (KURA) Net Income towards Common Stockholders (2010 - 2026)
Kura Oncology's (KURA) quarterly Net Income towards Common Stockholders came in at -$73.3 million in Q1 2026, down 27.69% year-on-year from -$101.4 million in Q1 2025, and up 9.46% on a QoQ basis from -$81.0 million in Q4 2025.
Kura Oncology (KURA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$73.3 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 27.69% year-over-year to -$73.3 million in Q1 2026; TTM through Mar 2026 was -$294.6 million, a 3626.85% decrease from a year earlier, with the FY2025 full-year figure at -$278.7 million, down 96996.17% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$73.3 million, up from -$81.0 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for KURA reached as high as $154.8 million in Q4 2024 and fell as low as -$81.0 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$39.1 million across 3 years, with a median of -$57.4 million in 2025.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 15.96% in 2025 and fell as far as 152.34% in 2025.
- Year by year, Net Income towards Common Stockholders stood at $154.8 million in 2024, then sank by 152.34% to -$81.0 million in 2025, then increased by 9.46% to -$73.3 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$73.3 million in Q1 2026, -$81.0 million in Q4 2025, and -$74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Kura Oncology | 928.19 Mn | 928.19 Mn | 18.00 Mn | -73.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | -81.00 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | 154.77 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2014 | -46,762.00 |
| Sep 30, 2014 | -6,428.00 |
| Jun 30, 2014 | -6,887.00 |
| Mar 31, 2014 | -5,766.00 |
| Dec 31, 2013 | -9,750.00 |
| Sep 30, 2013 | -6,139.00 |
| Jun 30, 2013 | -6,749.00 |
| Mar 31, 2013 | -5,973.00 |
| Dec 31, 2012 | -9,662.00 |
| Sep 30, 2012 | -6,013.00 |
| Jun 30, 2012 | -6,268.00 |